Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l
An Analysis of the PROVE-IT TIMI-22 Trial
Paul M. Ridker, MD*, ,*,
David A. Morrow, MD, ,
Lynda M. Rose, MS*,,
Nader Rifai, PhD*,,
Christopher P. Cannon, MD and
Eugene Braunwald, MD
* Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
The Donald W. Reynolds Center for Cardiovascular Research, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
The Thrombolysis In Myocardial Infarction (TIMI) Study Group, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts.
View larger version (16K):
[in a new window]
|
Figure 1 Cumulative incidence of recurrent myocardial infarction or coronary death in the PROVE-IT TIMI-22 trial among those who did and did not achieve the dual goals of low-density lipoprotein cholesterol (LDL-C) <70 mg/dl and high-sensitivity C-reactive protein (hsCRP) <2 mg/l. Cumulative incidence for those who achieved LDL-C <70 and the even lower hsCRP goal of <1 mg/l is also shown (dotted line).
|
|
View larger version (16K):
[in a new window]
|
Figure 2 Proportion of patients treated with atorvastatin 80 mg (black bars) and pravastatin 40 mg (white bars) who achieved low-density lipoprotein cholesterol (LDL-C) levels <70 mg/dl and high-sensitivity C-reactive protein (hsCRP) levels <2, <1.5, <1, and <0.5 mg/l. Data are shown for measures taken after 30 days of therapy, after 4 months of therapy, and at the end of study.
|
|
|
